Literature DB >> 24220357

Evaluation of 3 approaches for assessing adherence to vaginal gel application in clinical trials.

Ariane van der Straten1, Helen Cheng, Barbara Mensch, Barbara Friedland, Lauren Katzen, Sarah Littlefield, Niall Buckley, Lilia Espinoza, Marla J Keller, Betsy C Herold, Mark H Einstein.   

Abstract

BACKGROUND: Accurate measurement of adherence to product use is an ongoing challenge in microbicide trials.
METHODS: We compared adherence estimates using 2 applicator tests (a dye stain assay [DSA] and an ultraviolet light assay [UVA]), the Wisebag (an applicator container that electronically tracks container openings), and self-reported adherence (ability, frequency, and percent missed doses). Healthy, HIV-negative, nonpregnant US women aged 23 to 45 years received a Wisebag and 32 applicators filled with placebo gel were instructed to insert 1 applicator daily for 30 days, returned the Wisebag and all applicators, and completed an exit interview. Emptied applicators were tested by UVA and then DSA, and scored by 2 blinded readers. Positive and negative controls were randomly included in applicator batches.
RESULTS: Among 42 women enrolled, 39 completed the study. Both DSA and UVA yielded similar sensitivity (97% and 95%) and specificity (79% and 79%). Two participants had fully inoperable Wisebags, and 9 had partially inoperable Wisebags. The proportion of participants considered to have high adherence (≥80%) varied: 43% (Wisebag), 46% (UVA), 49% (DSA), and 62% to 82% (self-reports). For estimating high adherence, Wisebag had a sensitivity of 76% (95% confidence interval, 50%-93%) and a specificity of 85% (95% confidence interval, 62%-97%) compared with DSA. Although 28% of participants reported forgetting to open the Wisebag daily, 59% said that it helped them remember gel use.
CONCLUSIONS: Dye stain assay and UVA performed similarly. Compared with these tests, self-reports overestimated and Wisebag underestimated adherence. Although Wisebag may encourage gel use, the applicator tests currently seem more useful for measuring use in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24220357      PMCID: PMC4130378          DOI: 10.1097/OLQ.0000000000000053

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  26 in total

1.  A comparison study of multiple measures of adherence to HIV protease inhibitors.

Authors:  H Liu; C E Golin; L G Miller; R D Hays; C K Beck; S Sanandaji; J Christian; T Maldonado; D Duran; A H Kaplan; N S Wenger
Journal:  Ann Intern Med       Date:  2001-05-15       Impact factor: 25.391

2.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

Review 3.  Weighing the gold in the gold standard: challenges in HIV prevention research.

Authors:  Nancy S Padian; Sandra I McCoy; Jennifer E Balkus; Judith N Wasserheit
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

4.  In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials.

Authors:  Deborah Tien; Roger L Schnaare; Feirong Kang; Gina Cohl; Timothy J McCormick; Thomas R Moench; Gustavo Doncel; Karen Watson; Robert W Buckheit; Mark G Lewis; Jill Schwartz; Karen Douville; Joseph W Romano
Journal:  AIDS Res Hum Retroviruses       Date:  2005-10       Impact factor: 2.205

Review 5.  Practical and conceptual challenges in measuring antiretroviral adherence.

Authors:  Karina M Berg; Julia H Arnsten
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

6.  Use of electronic monitoring induces a 40-day intervention effect in HIV patients.

Authors:  Ann E Deschamps; Eric Van Wijngaerden; Kris Denhaerynck; Sabina De Geest; Anne-Mieke Vandamme
Journal:  J Acquir Immune Defic Syndr       Date:  2006-10-01       Impact factor: 3.731

7.  Optimal recall period and response task for self-reported HIV medication adherence.

Authors:  Minyi Lu; Steven A Safren; Paul R Skolnik; William H Rogers; William Coady; Helene Hardy; Ira B Wilson
Journal:  AIDS Behav       Date:  2007-06-19

8.  Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial.

Authors:  Stephanie Skoler-Karpoff; Gita Ramjee; Khatija Ahmed; Lydia Altini; Marlena Gehret Plagianos; Barbara Friedland; Sumen Govender; Alana De Kock; Nazira Cassim; Thesla Palanee; Gregory Dozier; Robin Maguire; Pekka Lahteenmaki
Journal:  Lancet       Date:  2008-12-06       Impact factor: 79.321

9.  Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials.

Authors:  Andrea R Wallace; Aaron Teitelbaum; Livia Wan; Maria Gloria Mulima; Laura Guichard; Stephanie Skoler; Stephanie Skiler; Hlengiwe Vilakazi; Fridda S Mapula; Jasmine Rossier; Sumen N Govender; Pekka Lahteenmaki; Robin A Maguire; David M Phillips
Journal:  Contraception       Date:  2007-05-11       Impact factor: 3.375

10.  Limitations of the dye-based method for determining vaginal applicator use in microbicide trials.

Authors:  Michele N Austin; Lorna K Rabe; Sharon L Hillier
Journal:  Sex Transm Dis       Date:  2009-06       Impact factor: 2.830

View more
  8 in total

1.  Adherence to rectal gel use among mainly ethnic minority young men who have sex with men during a 3-month placebo gel trial: implications for microbicide research.

Authors:  Alex Carballo-Diéguez; Rebecca Giguere; Curtis Dolezal; José Bauermeister; Cheng-Shiun Leu; Juan Valladares; Timothy Frasca; Rita Labbett; Ross D Cranston; Irma Febo; Kenneth Mayer; Ian McGowan
Journal:  AIDS Behav       Date:  2014-09

2.  Feasibility and Acceptability of Real-Time Antiretroviral Adherence Monitoring among Depressed Women Living with HIV in the Deep South of the US.

Authors:  Kristi Lynn Stringer; Andres Azuero; Corilyn Ott; Christina Psaros; Christina H Jagielski; Steven A Safren; Jessica E Haberer; Mirjam-Colette Kempf
Journal:  AIDS Behav       Date:  2019-05

3.  Exit interviews administered to patients participating in the COSTOP placebo controlled randomised trial in Uganda.

Authors:  Andrew Nunn; Zacchaeus Anywaine; Janet Seeley; Paula Munderi; Jonathan Levin; Ronnie Kasirye; Anatoli Kamali; Andrew Abaasa; Heiner Grosskurth
Journal:  Contemp Clin Trials Commun       Date:  2016-08-15

4.  Vaginal progesterone to prevent preterm delivery among HIV-infected pregnant women in Zambia: A feasibility study.

Authors:  Joan T Price; Winifreda M Phiri; Bethany L Freeman; Bellington Vwalika; Jennifer Winston; Chileshe M Mabula-Bwalya; Helen B Mulenga; Jeffrey S A Stringer
Journal:  PLoS One       Date:  2020-01-29       Impact factor: 3.240

5.  Development of a composite measure of product adherence, protocol compliance, and semen exposure using DNA and protein biomarkers for topical HIV prevention studies.

Authors:  Terry A Jacot; Ashley Nelson; Andrea Thurman; Angela D M Kashuba; David F Archer; Gustavo F Doncel
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

Review 6.  Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings.

Authors:  Randy M Stalter; Thomas R Moench; Kathleen M MacQueen; Elizabeth E Tolley; Derek H Owen
Journal:  J Int AIDS Soc       Date:  2016-05-02       Impact factor: 5.396

7.  Vaginal progesterone to reduce preterm birth among HIV-infected pregnant women in Zambia: a feasibility study protocol.

Authors:  Joan T Price; Katie R Mollan; Nurain M Fuseini; Bethany L Freeman; Helen B Mulenga; Amanda H Corbett; Bellington Vwalika; Jeffrey S A Stringer
Journal:  Pilot Feasibility Stud       Date:  2017-07-18

8.  Acceptability of a trial of vaginal progesterone for the prevention of preterm birth among HIV-infected women in Lusaka, Zambia: A mixed methods study.

Authors:  Joan T Price; Chileshe M Mabula-Bwalya; Bethany L Freeman; Jessica Carda-Auten; Winifreda M Phiri; Kasapo Chibwe; Patricia Kantumoya; Bellington Vwalika; Jeffrey S A Stringer; Carol E Golin
Journal:  PLoS One       Date:  2020-09-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.